Medine.co.uk

Montelukast 5mg Chewable Tablets

Informations for option: Montelukast 5mg Chewable Tablets, show other option
Document: leaflet MAH GENERIC_PL 40378-0100 change

Package leaflet: Information for the patient Montelukast 5 mg chewable tablets

montelukast

Read all of this leaflet carefully before you or your child starts taking this medicine because it contains important information for you.

•    Keep this leaflet. You may need to read it again.

•    If you have any further questions, ask your doctor, pharmacist or nurse.

•    This medicine has been prescribed for you or your child only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours or your child’s.

•    If you or your child gets any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

In this leaflet:

1.    What Montelukast is and what it is used for

2.    What you need to know before you take Montelukast

3.    How to take Montelukast

4.    Possible side effects

5.    How to store Montelukast

6.    Contents of the pack and other information

1. What Montelukast is and what it is used for

Montelukast is a leukotriene receptor antagonist that blocks substances called leukotrienes. Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking leukotrienes, Montelukast improves asthma symptoms and helps control asthma.

Your doctor has prescribed Montelukast to treat you or your child’s asthma, preventing asthma symptoms during the day and night.

•    Montelukast is used for the treatment of patients who are not adequately controlled on their medication and need additional therapy.

•    Montelukast may also be used as an alternative treatment to inhaled corticosteroids for 6 to 14 year old patients who have not recently taken oral corticosteroids for their asthma and have shown that they are unable to use inhaled corticosteroids.

•    Montelukast also helps prevent the narrowing of airways triggered by exercise.

Your doctor will determine how Montelukast should be used depending on the symptoms and severity of your or your child's asthma.

What is asthma?

Asthma is a long-term disease.

Asthma includes:

•    difficulty breathing because of narrowed airways. This narrowing of airways worsens and improves in response to various conditions.

•    sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.

•    swelling (inflammation) in the lining of the airways.

Symptoms of asthma include: Coughing, wheezing, and chest tightness.

2. What you need to know before you take Montelukast

Tell your doctor about any medical problems or allergies you or your child has now or has had.

Do not take Montelukast or give Montelukast to your child if you or he/she

•    Is allergic to montelukast or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist or nurse before taking Montelukast

•    If your or your child’s asthma or breathing gets worse, tell your doctor immediately.

•    Oral Montelukast is not meant to treat acute asthma attacks. If an attack occurs, follow the instructions your doctor has given you or your child. Always have your or your child’s inhaled rescue medicine for asthma attacks with you.

•    It is important that you or your child take all asthma medications prescribed by your doctor.

Montelukast should not be used instead of other asthma medications your doctor has prescribed for you or your child.

•    If you or your child is on anti-asthma medicines, be aware that if you or he/she develops a combination of symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your doctor.

•    You or your child should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medicines (also known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make your or his/her asthma worse.

Children and adolescents

For children 2 to 5 years old, Montelukast 4 mg chewable tablets and Montelukast 4 mg granules are available.

For children and adolescents 6 to 14 years old, Montelukast 5 mg chewable tablets are available.

Other medicines and Montelukast

Some medicines may affect how Montelukast works, or Montelukast may affect how your or your child’s other medicines work.

Tell your doctor or pharmacist if you or your child is taking, has recently taken or might take any other medicines, including those obtained without a prescription.

Tell your doctor if you or your child is taking the following medicines before starting Montelukast:

•    phenobarbital (used for treatment of epilepsy)

•    phenytoin (used for treatment of epilepsy)

•    rifampicin (used to treat tuberculosis and some other infections)

Montelukast with food and drink

Montelukast 5 mg chewable tablets should not be taken immediately with food; they should be taken at least 1 hour before or 2 hours after food.

Pregnancy and breast-feeding

Use in pregnancy

If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will assess whether you can take Montelukast during this time.

Use in breast-feeding

It is not known if Montelukast appears in breast milk. If you are breast-feeding or intend to breast-feed, ask your doctor for advice before taking this medicince.

Driving and using machines

Montelukast is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported very rarely with Montelukast may affect some patients’ ability to drive or operate machinery.

Montelukast 5 mg chewable tablets contain aspartame, a source of phenylalanine

If you or your child have phenylketonuria (a rare, hereditary disorder of the metabolism) you should take into account that each 5 mg chewable tablet contains phenylalanine (equivalent to 0.84 mg phenylalanine per 5 mg chewable tablet).

3.    How to take Montelukast

•    You or your child should take only one tablet of Montelukast once a day as prescribed by your doctor.

•    It should be taken even when you or your child has no symptoms or if you or your child has an acute asthma attack.

•    Always take this medicine exactly as your doctor or pharmacist has told you. Check with your or your child’s doctor or pharmacist if you are not sure.

•    To be taken by mouth

For children 6 to 14 years of age:

The recommended dose is one 5 mg chewable tablet daily to be taken in the evening. Montelukast 5 mg chewable tablets should not be taken immediately with food; it should be taken at least 1 hour before or two hours after food.

If you or your child is taking Montelukast, be sure that you or your child does not take any other products that contain the same active ingredient, montelukast.

If you or your child takes more Montelukast than you/he/she should

Contact your or your child’s doctor immediately for advice.

There were no side effects reported in the majority of overdose reports. The most frequently occurring symptoms reported with overdose in adults and children included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.

If you forget to take Montelukast or give Montelukast to your child

Try to take Montelukast as prescribed. However, if you or your child misses a dose, just resume the usual schedule of one tablet once daily.

Do not take a double dose to make up for a forgotten dose.

If you or your child stops taking Montelukast

Montelukast can treat your or your child’s asthma only if you or your child continues taking it.

It is important for you or your child to continue taking Montelukast for as long as your doctor prescribes. It will help control your or your child’s asthma.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

In clinical studies with Montelukast 5 mg chewable tablets, the most commonly reported side effects (occurring in at least 1 of 100 patients and less than 1 of 10 paediatric patients treated) thought to be related to Montelukast were:

•    headache

Additionally, the following side effect was reported in clinical studies with Montelukast 10 mg film-coated tablets:

•    abdominal pain

These were usually mild and occurred at a greater frequency in patients treated with Montelukast than placebo (a pill containing no medication).

The frequency of possible side effects listed below is defined using the following convention: Very common (affects at least 1 user in 10)

Common (affects 1 to 10 users in 100)

Uncommon (affects 1 to 10 users in 1,000)

Rare (affects 1 to 10 users in 10,000)

Very rare (affects less than 1 user in 10,000)

Additionally, while the medicine has been on the market, the following have been reported:

•    Upper respiratory infection (Very common)

   Increased bleeding tendency (Rare)

   Allergic reactions including rash, swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing (Uncommon)

   Behaviour and mood related changes [dream abnormalities, including nightmares, trouble sleeping, sleep walking, irritability, feeling anxious, restlessness, agitation including aggressive behaviour or hostility, depression (Uncommon); tremor (Rare); hallucinations, suicidal thoughts and actions (Very rare)]

   Dizziness, drowsiness, pins and needles/numbness, seizure (Uncommon)

   Palpitations (Rare)

•    Nosebleed (Uncommon)

   Diarrhoea, nausea, vomiting (Common); dry mouth, indigestion (Uncommon)

   Hepatitis (inflammation of the liver) (Very rare)

   Bruising, itching, hives (Uncommon); tender red lumps under the skin most commonly on your shins (erythema nodosum) (Very rare)

   Joint or muscle pain, muscle cramps (Uncommon)

   Fever (Common); tiredness, feeling unwell, swelling (Uncommon)

In asthmatic patients treated with montelukast, very rare cases of a combination of symptoms such as flu-like illness, pins and needles or numbness of arms and legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) have been reported. You must tell your doctor right away if you or your child gets one or more of these symptoms.

Ask your doctor or pharmacist for more information about side effects. If you or your child gets any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in this leaflet.

5.    How to store Montelukast

•    Keep this medicine out of the sight and reach of children.

•    Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

•    Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6.    Contents of the pack and other information

What Montelukast 5 mg chewable tablets contain

•    The active substance is montelukast. Each Montelukast 5 mg tablet contains montelukast sodium which corresponds to 5 mg of montelukast.

•    The other ingredients are: microcrystalline cellulose, hydroxypropylcellulose, croscarmellose sodium, lactose monohydrate, iron oxide red (E172), mannitol, silarom cherry flavour, aspartame, magnesium stearate.

What Montelukast 5 mg chewable tablets look like and contents of the pack

5 mg Montelukast chewable tablets are pink, mottled, round, biconvex tablets with M5

engraved on one side.

Blisters in packages of:

7.    10, 14, 20, 28, 30, 49, 50, 56, 98, 100, 140 and 200 tablets

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:

Aptil Pharma Limited

9th Floor, CP House

97-107 Uxbridge Road, Ealing

London

W5 5TL

Manufacturer:

Actavis Ltd

BLB 016 Bulebel Industrial Estate

Zejtun ZTN 3000

Malta

This leaflet was last revised in November 2012.